Propanc Biopharma (PPCB) Long-Term Debt Repayments (2015 - 2025)
Propanc Biopharma (PPCB) posted quarterly Long-Term Debt Repayments of $203350.0 for Q3 2025, up 42.2% year-over-year from $143000.0 in Q3 2024, and up 50.63% quarter-over-quarter from $135000.0 in Q2 2025.
Propanc Biopharma (PPCB) Long-Term Debt Repayments (2015 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Long-Term Debt Repayments for 8 consecutive years, with $203350.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Long-Term Debt Repayments rose 42.2% year-over-year to $203350.0; the TTM figure through Dec 2025 stood at $203350.0 (up 42.2% YoY), while the FY2025 annual figure was $143000.0, changed 0.06% from the prior year.
- Long-Term Debt Repayments climbed to $203350.0 in Q3 2025 per PPCB's latest filing, from $135000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $203350.0 in Q3 2025 and bottomed at -$135000.0 in Q1 2025.
- Historically, Long-Term Debt Repayments has averaged $97851.8 across 3 years, with a median of $142909.0 in 2023.
- Annual changes were most pronounced in 2024 — Long-Term Debt Repayments grew 0.06% — and 2025, when it jumped 42.2%.
- Propanc Biopharma's Long-Term Debt Repayments stood at $142909.0 in 2023, then increased by 0.06% to $143000.0 in 2024, then surged by 42.2% to $203350.0 in 2025.
- Business Quant data shows PPCB's Long-Term Debt Repayments at $203350.0 in Q3 2025, $135000.0 in Q2 2025, and -$135000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 17.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -10.01 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 203,350.00 |
| Sep 30, 2025 | 203,350.00 |
| Jun 30, 2025 | 135,000.00 |
| Jun 30, 2025 | 135,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Mar 31, 2025 | -135,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Sep 30, 2024 | 143,000.00 |
| Sep 30, 2023 | 142,909.00 |
| Sep 30, 2023 | 142,909.00 |
| Sep 30, 2020 | 43,000.00 |
| Sep 30, 2020 | 43,000.00 |
| Mar 31, 2019 | 53,000.00 |
| Mar 31, 2019 | 53,000.00 |
| Dec 31, 2018 | 166,000.00 |
| Dec 31, 2018 | 166,000.00 |
| Sep 30, 2018 | 53,000.00 |
| Sep 30, 2018 | 53,000.00 |
| Jun 30, 2016 | -62,500.00 |
| Jun 30, 2016 | -62,500.00 |